COMMUNIQUÉS West-GlobeNewswire

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
26/06/2025
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. GAITHERSBURG, Md., June 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing [...]
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
26/06/2025
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and [...]
Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
25/06/2025
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant [...]
Neurosculpting Institute Announces Peer-Reviewed Study Linking Neurosculpting Meditation to Improved Clinical Accuracy in Dental Students
25/06/2025
Denver, CO , June 25, 2025 (GLOBE NEWSWIRE) -- The Neurosculpting® Institute , a meditation and neuroplasticity education organization, announced the publication of a peer-reviewed study in the Cureus Journal of Medical [...]
Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer
25/06/2025
SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh [...]
Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City
25/06/2025
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that it will host an R&D Day in New York City on Wednesday, July 9, 2025 beginning at 8:30 am [...]
Kymera Therapeutics Announces Proposed Public Offering
25/06/2025
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Option Care Health to Announce Second Quarter 2025 Financial Results and Host Conference Call
25/06/2025
BANNOCKBURN, Ill., June 25, 2025 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent provider of home and alternate site infusion services, today announced [...]
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET
25/06/2025
HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for [...]
DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide.
25/06/2025
Châtillon, France, le 25 juin (22 :30 CEST) 2025 DBV Technologies annonce le screening du premier sujet de l'étude complémentaire d’innocuité COMFORT Toddlers chez les enfants âgés de 1 à 3 ans allergiques à l’arachide [...]
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
25/06/2025
Châtillon, France, June 25, 2025 DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old First subject screened at the Respiratory [...]
HNL Lab Medicine Announces Art Contest Winners
25/06/2025
ALLENTOWN, Pa., June 25, 2025 (GLOBE NEWSWIRE) -- HNL Lab Medicine, a leading medical diagnostics laboratory, is proud to announce the winners of its Annual Children’s Art Contest! This year’s theme invited students to [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
25/06/2025
CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025
25/06/2025
TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday [...]
Coalition to Improve Access to Cancer Care Applauds Reintroduction of the Cancer Drug Parity Act
25/06/2025
WASHINGTON, June 25, 2025 (GLOBE NEWSWIRE) -- The Coalition to Improve Access to Cancer Care (CIACC) applauds the reintroduction of the Cancer Drug Parity Act, bipartisan legislation that would require group and [...]
Main Results of 2025 Annual and Extraordinary General Meeting
25/06/2025
The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg, Grand Duchy of Luxembourg. All of [...]
Main Results of 2025 Annual and Extraordinary General Meeting
25/06/2025
REYKJAVÍK, Iceland and LUXEMBOURG, June 25, 2025 (GLOBE NEWSWIRE) -- The 2025 Annual and Extraordinary General Meeting (the "2025 AGM") of Alvotech (the "Company") was held on June 25, 2025, at Arendt House, 41A Avenue [...]
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
25/06/2025
- Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis -RemeGen receives [...]
Vor Bio Announces $175 Million Private Placement
25/06/2025
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities [...]

Pages